The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

Chinese AI drug firm XtalPi expands Singapore partnership

10.30

Under the MARVEL-AI program, the companies will develop new materials using computational tools and automated laboratory experiments.

Funding & deals

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

Chinese AI drug firm XtalPi expands Singapore partnership

Related

AsiaThese are Asia’s most active investors in AI Tech in Asia

ValleyWabi reels in $55M for its consumer-focused AI assistant SiliconANGLE

ValleyOpenAI-backed Thrive Holdings acquires ADT TechCrunch AI

AsiaKlassroom H1: Profit Jumps 24% YoY To ₹4 Cr, Revenue Up 21% Inc42

ValleyScience robotics startup Opentrons raises $40M to standardize laboratory automation SiliconANGLE

AsiaBijnis Rebrands As Zorit, Raises ₹27 Cr For B2B Quick Commerce Inc42